F. Andrea

A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.

I. Bondarenko, M. Reck, N. Kovalenko, 2020, Lung Cancer.

A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC

I. Bondarenko, M. Reck, N. Kovalenko, 2019, Annals of Oncology.